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Abstract
Introduction Interleukin (IL)-17 is a pro-inflammatory cytokine in
rheumatoid arthritis (RA) and collagen-induced arthritis (CIA).
Since interferon (IFN)-γ inhibits Th17 cell development, IFN-γ
receptor knockout (IFN-γR KO) mice develop CIA more readily.
We took advantage of this model to analyse the mechanisms of
action of IL-17 in arthritis. The role of IFN-γ on the effector
mechanisms of IL-17 in an in vitro system was also investigated.
Methods IFN-γR KO mice induced for CIA were treated with
anti-IL-17 or control antibody. The collagen type II (CII)-specific
humoral and cellular autoimmune responses, myelopoiesis,
osteoclastogenesis, and systemic cytokine production were
determined. Mouse embryo fibroblasts (MEF) were stimulated
with IL-17, tumor necrosis factor (TNF)-α and the expression of
cytokines and chemokines were determined.
Results A preventive anti-IL-17 antibody treatment inhibited CIA
in IFNγR KO mice. In the joints of anti-IL-17-treated mice,
neutrophil influx and bone destruction were absent. Treatment
reduced the cellular autoimmune response as well as the
splenic expansion of CD11b+  cells, and production of
myelopoietic cytokines such as granulocyte macrophage
colony-stimulating factor (GM-CSF) and IL-6. IL-17 and TNF-α
synergistically induced granulocyte chemotactic protein-2
(GCP-2), IL-6 and receptor activator of NFκB ligand (RANKL) in
MEF. This induction was profoundly inhibited by IFN-γ in a
STAT-1 (signal transducer and activator of transcription-1)-
dependent way.
Conclusions In the absence of IFN-γ, IL-17 mediates its pro-
inflammatory effects mainly through stimulatory effects on
granulopoiesis, neutrophil infiltration and bone destruction. In
vitro  IFN-γ profoundly inhibits the effector function of IL-17.
Thus, aside from the well-known inhibition of the development of
Th17 cells by IFN-γ, this may be an additional mechanism
through which IFN-γ attenuates autoimmune diseases.
CFA: complete Freund's adjuvant; CHO: Chinese hamster ovary; CIA: collagen-induced arthritis; CII: collagen type II; DTH: delayed type hypersen-
sitivity; ELISA: enzyme-linked immunosorbent assay; EMEM: Eagle's minimal essential medium; FCS: fetal calf serum; FITC: fluorescein isothiocy-
anate; GCP-2: granulocyte chemotactic protein-2; G-CSF: granulocyte colony-stimulating factor; GM-CSF: granulocyte macrophage colony-
stimulating factor; IFN: interferon; IFN-γR KO: interferon-γ receptor knock-out; IL: interleukin; IP-10: interferon-gamma-induced protein; IRF: interferon 
regulatory factor; ITAC: interferon-inducible T cell alpha chemoattractant; KC: keratinocyte-derived chemokine; MCP: monocyte chemotactic protein; 
M-CSF: macrophage colony-stimulating factor; MEF: mouse embryo fibroblasts; MIG: monokine induced by gamma interferon; MIP: macrophage 
inflammatory protein; PBS: phosphate buffered saline; PCR: polymerase chain reaction; PE: phycoerythrin; RA: rheumatoid arthritis; RANKL: receptor 
activator of nuclear factor-κB ligand; RANTES: Regulated upon Activation, Normal T-cell Expressed, and Secreted; STAT: signal transducer and acti-
vator of transcription; TGF-β: transforming growth factor-β; TNF-α: tumor necrosis factor-α.Arthritis Research & Therapy    Vol 11 No 4    Kelchtermans et al.
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Introduction
IL-17 is a pro-inflammatory cytokine produced by activated
CD4+ T cells distinct from Th1 or Th2 cells, designated as
Th17 cells [1-3]. IL-17 promotes inflammation by enhancing
production of cytokines such as IL-1β, TNF-α, IL-6 and recep-
tor activator of nuclear factor-κB ligand (RANKL), as well as
chemokines such as macrophage inflammatory protein (MIP)-
2 and IL-8 [4-6]. Factors that promote Th17 cell differentiation
and/or expansion are transforming growth factor (TGF)-β, IL-6
and IL-23 [7]. Interferon (IFN)-γ, as a contrast, strongly inhibits
development of Th17 cells both in vitro and in vivo [1,3,8].
Anti-IFN-γ added during in vitro Th17 differentiation causes
increased IL-17 expression, and treated cells display
increased expression of the IL-23 receptor (R) [3]. This,
together with the observation that IFN-γ decreases the expres-
sion of IL-23R in IFN-γ-deficient CD4+ T cells differentiated
towards a Th17 phenotype, indicates that IFN-γ is able to
inhibit expression of the IL-23R. Additionally, IFN-γ-deficient
mice have increased numbers of IL-17-producing T cells fol-
lowing mycobacterial infection as compared with wild-type
mice, and exogenous IFN-γ reduces the frequency of IL-17-
producing T cells in IFN-γ-deficient mice [9].
There is considerable evidence that IL-17 contributes to the
inflammation associated with rheumatoid arthritis (RA). IL-17
is spontaneously produced by RA synovial membrane cultures
and high levels of IL-17 were detected in the synovial fluid of
patients with RA [10,11]. In collagen-induced arthritis (CIA),
an animal model reminiscent in several aspects to RA, treat-
ment with neutralizing anti-IL-17 antibody after the onset of
arthritis reduces joint inflammation, cartilage destruction and
bone erosion [12]. Authors proposed that the mechanisms
responsible for slowing the disease are suppression of pro-
inflammatory cytokines, such as IL-1β, TNF-α and IL-6, and
elimination of the additive/synergistic effects between IL-17
and these pro-inflammatory cytokines. In addition, mice genet-
ically deficient in IL-17 or IL-17R were found to be less sus-
ceptible for induction of CIA [13]. In contrast, local IL-17
overexpression accelerates the onset of CIA and aggravates
synovial inflammation [14]. Evidence that IFN-γ regulates sus-
ceptibility to CIA through suppression of IL-17 comes from the
observation that mice of the prototypical CIA-susceptible
strain DBA/1 demonstrate a high IL-17 and low IFN-γ cytokine
profile as compared with CIA-resistant C57BL/6 mice [15]. In
addition, knocking out the IFN-γ gene renders the C57BL/6
mice susceptible to disease and switched their CD4+ T cell
differentiation towards Th17.
Despite the exciting new knowledge about Th17 cells and IL-
17, their mechanisms of action in the pathogenesis of arthritis
are still unclear. In the present study we investigated pro-
inflammatory characteristics of IL-17 using the CIA model. As
IFN-γ is counteracting the development of Th17 cells, we
chose to induce CIA in IFN-γR knock out (KO) mice. Through
neutralization of IL-17 using monoclonal anti-IL-17 antibody,
we tested the effect of endogenous IL-17 on various potential
effector targets of CIA, such as autoimmune cellular and
humoral responses, production of cytokines and chemokines,
stimulation of hematopoiesis and osteoclastogenesis. We
found a clear-cut inhibition of CIA by treatment with anti-IL-17
antibody and the protection was associated with profound
inhibition of myelopoiesis and production of myelopoietic
cytokines. Extensive myelopoiesis is a well-described phe-
nomenom in IFN-γR KO mice challenged with (auto)antigen in
complete Freund's adjuvant (CFA; reviewed in [16,17]), so in
an in vitro system using murine embryo fibroblast (MEF) cells
we verified whether IL-17 may directly be involved in the induc-
tion of myelopoietic cytokines and/or chemokines and whether
IFN-γ may influence this process.
Materials and methods
Antibodies and cytokines
Recombinant mouse IFN-γ was derived from the supernatant
fluid of Mick cells, a Chinese hamster ovary (CHO) cell line
developed in our laboratory [18]. IFN-γ was purified by affinity
chromatography to a specific activity of 108.5units/mg as
described [19].
Anti-IL-17A antibody MM17F3 (IgG1-K) was derived from
C57Bl/6 mice immunized with IL-17A-ovalbumin complexes
as described [20]. Murine IgG1 monoclonal antibody (9E10),
that recognizes part of the human c-myc protein, and is pro-
duced by the MYC1-9E10.2 (ATCC CRL 1729) hybridoma,
was used as control antibody [21].
Mice, induction, evaluation and treatment of CIA
Generation and basic characteristics of the mutant mouse
strain (129/Sv/Ev) with a disruption in the gene encoding for
the α-chain of the IFN-γ R (IFN-γR KO) have been described
[22]. These IFN-γR KO mice were backcrossed with wild-type
DBA/1 mice for 10 generations to obtain IFN-γR KO DBA/1
mice. Homozygous IFN-γR KO mice were identified by PCR as
described [23]. Wild-type and IFN-γR KO DBA/1 mice were
bred in the Experimental Animal Centre of the Rega Institute
for Medical Research at Leuven.
The generation and basic characterization of IFN-γ-deficient
mice of the 129 × BALB/c strain have been described [24].
These mice were backcrossed for eight generations to the
parental BALB/c strain. The signal transducer and activator of
transcription (STAT)-1-/- and interferon regulatory factor (IRF)-
1-/- mice, on a C57BL/6 background, were from Dr. David E.
Levy of the New York University School of Medicine (New
York, USA) and from Dr. Tak Mak of the Ontario Cancer Insti-
tute (Ontario, Canada), respectively. The generation and char-
acteristics of these mice have been described [25,26].
C57BL/6 mice (Harlan, Zeist, the Netherlands) were used as
wild-type controls.Available online http://arthritis-research.com/content/11/4/R122
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Chicken collagen type II (CII; Sigma-Aldrich, St Louis, MO,
USA) was dissolved at 2 mg/ml in PBS containing 0.1 M ace-
tic acid by stirring overnight at 6°C and emulsified in an equal
volume of CFA (Difco Laboratories, Detroit, MI, USA) with
added heat-killed Mycobacterium butyricum (1.5 mg/ml). Mice
were sensitized with a single intradermal injection at the base
of the tail with 100 μl of the emulsion on day 0, and treated
with 0.2 mg of neutralizing anti-IL-17 or control antibody (in
250 μl PBS) once a week. Clinical and histological severity of
arthritis were recorded following a scoring system as
described [27,28].
All animal experiments were approved by the local ethical com-
mittee (University of Leuven).
Measurement of total and anti-CII IgG antibodies and 
delayed-type hypersensitivity to CII
Blood samples were taken from the orbital sinus and were
allowed to clot at room temperature for one hour and at 4°C
overnight. Individual sera were tested for antibodies directed
to chicken CII by ELISA as described [27]. For the determina-
tion of CII-specific IgG1, IgG2a and IgG2b antibody, plates
were incubated for two hours with biotinylated rat antibody to
mouse IgG1, IgG2a or IgG2b (Zymed Laboratories, San Fran-
cisco, CA, USA), followed by a one-hour incubation with
streptavidin-conjugated peroxidase. For measurement of total
IgG antibody, plates were coated with goat anti-mouse IgG
(Jackson Immunoresearch Laboratories, West Grove, PA,
USA; 10 μg/ml; 100 μl/well), followed by the same procedure
as described in [27].
For evaluation of delayed-type hypersensitivity (DTH) reactiv-
ity, CII/CFA-immunized mice were subcutaneously injected
with 20 μg of CII/20 μl PBS in the left ear and with 20 μl PBS
in the right ear. DTH response was calculated as the percent-
age swelling (the difference between the increase of thickness
of the left ear and the right ear, divided by the thickness of the
right ear, multiplied by 100).
Isolation of splenocytes and mouse embryo fibroblasts
Spleens were harvested, gently cut into small pieces and
passed through cell strainers (Becton Dickinson Labware,
Franklin Lakes, NJ, USA). Red blood cells were lysed by two
consecutive incubations (5 and 3 minutes at 37°C) of the sus-
pension in NH4Cl (0.83% in 0.01 M Tris-HCl, pH 7.2).
Remaining cells were washed and counted.
To exclude any interference from endogenous IFN-γ, MEF
were from IFN-γ KO BALB/c origin (unless otherwise men-
tioned). MEF were isolated from mouse embryos between 16
and 18 days of gestation, as described [28]. Two times 105
MEF in a total volume of 300 μl Eagle's minimal essential
medium (EMEM) containing 2% heat-inactivated FCS were
seeded in chamber slides (LAB-TEK Brand Products, Nalge
Nunc International, Naperville, IL, USA). After an incubation of
48 hours, cells were stimulated with IL-17 (20 ng/ml) (R&D
systems, Abingdon UK) and/or TNF-α (20 ng/ml) (R&D sys-
tems, Abingdon UK) in the presence or absence of IFN-γ (100
units/ml) for 48 hours. Supernatants were collected and cells
were harvested using a cell scraper (LAB-TEK Brand Prod-
ucts, Nalge Nunc International, Naperville, IL, USA). Cells
were washed and pellets were used for PCR.
Flow cytometry
Single-cell splenocyte suspensions (0.5 × 106 cells) were
incubated for 15 minutes with the Fc-receptor-blocking anti-
bodies anti-CD16/anti-CD32 (BD Biosciences Pharmingen,
San Diego, CA, USA). Cells were washed with PBS (2%
FCS) and stained with the indicated fluorescein isothiocy-
anate (FITC)-conjugated antibodies (0.5 μg) for 30 minutes,
washed and incubated with the indicated phycoerythrin (PE)-
conjugated antibodies for 30 minutes. FITC-conjugated anti-
CD25 (7D4) and FITC-conjugated anti-B220 were purchased
from BD Biosciences Pharmingen, San Diego, CA, USA).
FITC-conjugated anti-CD11b (M1/70), FITC-conjugated anti-
CD8 (53-6.7), PE conjugated anti-CD4 (L3T4), and PE-conju-
gated anti-Gr-1 (RB6-8C5) were from eBioscience (Immuno-
Source, Halle-Zoersel, Belgium). Cells were washed, fixed
with 0.37% formaldehyde in PBS and flowcytometric analysis
was performed on a FACScan flow cytometer with Cell
Quest® software (Becton Dickinson, San Jose, CA, USA).
Detection of cytokines by quantitative PCR and ELISA
MEF were obtained as described above. RNA was extracted
using the Micro-to-Midi Total RNA Purification System (Invitro-
gen Life Technologies, Carlsbad, CA, USA) in accordance
with the manufacturer's instructions. cDNA was obtained by
reverse transcription using Superscript II Reverse Tran-
scriptase and random primers (Invitrogen Life Technologies,
Carlsbad, CA, USA), in accordance with the manufacturer's
instructions. For real-time PCR we used a TaqMan® Assays-
on-Demand™ Gene expression Product from Applied Biosys-
tems (Foster City, CA, USA). Expression levels of granulocyte
chemotactic protein-2 (GCP-2) (assay ID Mm00436451_g1,
Applied Biosystems, Foster City, CA, USA), IL-6 (assay ID
Mm00446190_m1, Applied Biosystems, Foster City, CA,
USA), RANKL (assay ID Mm00441908_m1, Applied Biosys-
tems, Foster City, CA, USA), IP-10 (assay ID
Mm99999072_m1) and granulocyte macrophage colony-
stimulating factor (GM-CSF; assay ID Mm99999059_m1)
were normalized for 18S RNA (Cat. No. 4319413E, Applied
Biosystems, Foster City, CA, USA) expression. Analysis was
performed in an ABI Prism 7000 apparatus (Applied Biosys-
tems, Foster City, CA, USA) under the following conditions:
inactivation of possible contaminating amplicons by AmpEr-
ase uracil-N-glycosylase at 50°C for two minutes, initial dena-
turation at 95°C for 10 minutes, followed by 40 thermal cycles
of 15 seconds at 95°C and 90 seconds at 60°C. The relative
gene expression was assessed using the 2-ΔΔCT method [29].Arthritis Research & Therapy    Vol 11 No 4    Kelchtermans et al.
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Expression of cytokines (i.e. IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10,
GM-CSF, IFN-γ and TNF-α) was determined by the Bio-Plex
200 system, Bio-plex Mouse Cytokine 8-plex assay and Bio-
plex Mouse IL-6 Assay (Bio-Rad, Hercules, CA). IL-17, IP-10
and GM-CSF levels were measured by ELISA (R&D systems,
Abingdon UK). GCP-2 was detected by an ELISA developed
in our laboratory, as described [28].
Results
Increased levels of IL-17 in CII/CFA-immunized IFN-γR 
KO mice
IFN-γR KO mice develop CIA more readily than wild-type con-
trols: symptoms of arthritis usually appear in IFN-γR KO mice
from day 16 onwards compared with day 30 in wild-type ani-
mals [30]. In a first experiment, we confirmed the inhibitory
activity of IFN-γ on the production of IL-17. Thus, IFN-γR KO
and wild-type mice were immunized with CII in CFA. At day 21,
a time point when the differences in disease symptoms
between both groups are most pronounced, mice were
injected with anti-CD3 and sera were collected. As expected,
levels of IL-17 were more than four times higher in the sera of
immunized IFN-γR KO mice as compared with those of wild-
type counterparts (Figure 1a, in vivo). Similarly, anti-CD3-stim-
ulated lymphocytes of immunized IFN-γR KO mice produced
levels of IL-17 that were more than 10 times higher than those
of wild-type mice (Figure 1a, in vitro). Therefore, to study the
effector functions of IL-17 in arthritis, we chose IFN-γR KO
mice for the induction of arthritis.
Figure 1
Treatment with anti-IL-17 antibody prevents CIA in IFN-γR KO mice Treatment with anti-IL-17 antibody prevents CIA in IFN-γR KO mice. (a) Interferon-γ receptor knock-out (IFN-γR KO) and wild-type mice were immu-
nized with collagen type II (CII) in complete Freund's adjuvant (in vivo). At day 21 post immunization, five IFN-γR KO and six wild-type mice were 
challenged with 10 μg anti-CD3 antibody and serum levels of IL-17 were determined 1.5 hours later. Bars represent averages ± standard error of 
the mean (SEM). In vitro: lymph nodes were isolated at day 35 post immunization, and lymphocytes were stimulated with 3 μg/ml anti-CD3 antibody. 
Supernatants were collected after 72 hours and tested for IL-17 expression. Bars represent averages ± SEM of triplicate cultures. * P < 0.05 for 
comparison with IFN-γR KO mice (Mann-Whitney U-test). (b, c) Immunized IFN-γR KO mice were injected with anti-IL-17 or control antibody. (b) 
Cumulative incidence of arthritis and (c) mean arthritic score of mice are shown. Error bars indicate SEM. Data are representative for three inde-
pendent experiments. * P < 0.05 (day 19) and 0.005 (from day 20 onwards) for comparison with control-treated mice (Mann-Whitney U-test). (d) 
The mean arthritic score on day 21 of arthritic mice only is shown for three experiments. Error bars indicate SEM. The number of arthritic mice to the 
total number of mice in each group is shown in brackets.Available online http://arthritis-research.com/content/11/4/R122
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Neutralization of IL-17 inhibits arthritis development in 
IFN-γR KO mice
CII/CFA-immunized IFN-γR KO mice were injected with neu-
tralizing anti-IL-17 or control antibody once a week starting
from day 0 (day of immunization). In control-treated IFN-γR KO
mice, symptoms of arthritis appeared from day 14 and reached
a cumulative incidence of approximately 92%. In contrast,
mice treated with anti-IL-17 antibody developed a significantly
less severe form of arthritis with a lower incidence (25%) than
control mice (Figures 1b, c). This protective effect was con-
firmed in two independent experiments. When the analysis
was restricted to only arthritic mice, severity of arthritis was still
lower in anti-IL-17-treated mice compared with control-treated
mice (Figure 1d). In one such experiment, mice were sacrificed
on day 25 for histological examination of the joints. As evident
from data in Figure 2a, the reduced severity of arthritis in anti-
IL-17-treated mice was associated with inhibition of infiltration
of mono- and polymorphonuclear cells, hyperplasia and pan-
nus formation (measured as the fraction of synovial inflamma-
tory tissue, which has invaded bone tissue and forms bone
erosion). In the control-treated group, several multinucleated
osteoclast-like cells were detected at sites of bone erosion.
Osteoclast-like cells and polymorphonuclear cells were com-
pletely absent in sections of anti-IL-17-treated mice. Figures
2b and 2c show light microscopy on hematoxylin-stained sec-
tions of both groups of mice.
Reduced humoral and cellular auto-immune responses 
in IFN-γR KO mice treated with anti-IL-17 antibodies
Pathogenesis of CIA is generally considered to depend in part
on both humoral and cellular immune responses against CII.
We wanted to define whether the protection against CIA by
anti-IL-17 antibodies results from modulation from either of
these. Total IgG and anti-CII IgG, IgG1, IgG2a and IgG2b
were determined in the sera of anti-IL-17- and control-treated
IFN-γR KO mice on day 22 post-immunization. No differences
in total IgG serum content were detected in the sera of anti-IL-
17- and control-treated animals (Figure 3a). Titers of anti-CII
antibodies were found to be reduced in the sera of anti-IL-17-
treated mice, although values did not reach statistical signifi-
cance (Figure 3b). As to subtypes of anti-CII IgG, no differ-
ences in anti-CII IgG1 and IgG2b could be detected.
However, levels of anti-CII IgG2a were significantly lower in
sera of anti-IL-17-treated IFN-γR KO mice as compared with
control-treated mice (Figure 3c). DTH was tested on day 25
after immunization by injecting 20 μg of CII in the left ears and
vehicle in the right ears. Bars in Figure 3d represent the per-
centages of swelling in the CII-challenged ears, normalized to
the swelling of the PBS-challenged ears. A significantly lower
DTH response to CII was observed in the anti-IL-17-treated
mice as compared with that in control mice. Thus, the reduced
severity of arthritis in anti-IL-17-treated mice appeared to be
associated with reduced cellular immune responsiveness to
CII.
Figure 2
Absence of infiltration of neutrophils and bone destruction in the joints of anti-IL-17-treated mice Absence of infiltration of neutrophils and bone destruction in the joints of anti-IL-17-treated mice. In experiment 1 of Figure 1d, histological analysis 
of the joints was performed. On day 25, four mice of each group were sacrificed and sections of the fore limbs, hind limbs and ankles were scored 
for three parameters of arthritis following hematoxylin staining. (a) Histograms represent averages ± standard error of the mean (SEM). * P < 0.005 
for comparison with control-treated mice (Mann-Whitney U-test). (b, c) Pictures of the hematoxylin-stained paraffin sections of the joints of control-
treated (b, a representative mouse) and anti-IL-17-treated (c, mice with the most severe symptoms) mice are shown. In control-treated mice, a severe 
hyperplasia and infiltration of immunocompetent cells in the synovium and pannus formation that penetrates into the bone can be seen. (b1, 2) Detail 
of the area indicated by respectively the left and right box in b. Note the presence of osteoclast-like multinucleated giant cells (arrows in b1), and the 
presence of polymorphonuclear cells in b2. (c1) Detail of the area indicated by the right box in c showing a moderate infiltration of mononuclear cells 
and hyperplasia. Scale bars represent (b, c) 50 μm and (b1, b2 and c1) 500 μm.Arthritis Research & Therapy    Vol 11 No 4    Kelchtermans et al.
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Inhibition of arthritis in IFN-γR KO mice is associated 
with reduced expansion of CD11b+ cells
The more severe form of arthritis in IFN-γR KO mice as com-
pared with wild-type mice is accompanied with an extramedul-
lary hemopoiesis and expansion of the CD11b+ cell population
[31]. These expanding CD11b+  splenocytes, containing
mostly immature mononuclear phagocytes and neutrophils,
can act as a source of osteoclasts and may thus indirectly
account for bone destruction in CIA [23] or may contribute to
neutrophil inflammation in the joints. IL-17 is known to stimu-
late granulopoiesis in vivo [32] and to induce the production
of hematopoietic cytokines such as IL-6, IL-8 and G-CSF in
vitro [5], so we analysed the effect of IL-17 neutralization on
the expansion of the CD11b+  cell expansion. Therefore,
spleens were isolated from anti-IL-17-treated and control-
treated IFN-γR KO mice on day 21 after immunization. The
mean number of splenocytes was significantly lower in mice
treated with anti-IL-17 as compared with control antibody (Fig-
ure 4a). To characterize these splenocytes, flowcytometric
analysis was performed. Figure 4b shows that the anti-IL-17
antibodies inhibit the expansion of the CD11b+ cell popula-
tion. In fact, treatment with anti-IL-17 antibodies resulted in
significantly lower net numbers of CD11b+Gr-1high neutrophils
in the spleen. Numbers of CD4+ and CD8+ T cells were also
significantly lower in anti-IL-17-treated mice, although to a
lesser degree. B220+ cell numbers were comparable in both
groups of mice. These data were confirmed by cytospin
splenocyte preparations (Figure 4c). Significantly lower num-
Figure 3
Reduced humoral and cellular immune response following treatment of CII/CFA immunized IFN-γR KO mice with anti-IL-17 antibodies Reduced humoral and cellular immune response following treatment of CII/CFA immunized IFN-γR KO mice with anti-IL-17 antibodies. Interferon-γ 
receptor knock-out (IFN-γR KO) mice were immunized and injected intraperitoneally with 0.2 mg of neutralizing anti-IL-17 or control antibody once a 
week. (a, b) On day 22, sera of individual mice were analyzed for (a) total IgG, (b) anti- collagen type II (CII) IgG and (c) anti-CII IgG1, IgG2a and 
IgG2b. Histograms represent averages ± standard error of the mean (SEM). (d) 25 days after immunization, mice in each group were challenged 
with 20 μg of CII in the left ear and vehicle in the right ear. Delayed type hypersensitivity responses were measured as the percentage of swelling 
(i.e. 100 × the difference between the increase of thickness of the left and the right ears, divided by the thickness of the right ear) at the indicated 
time points. Histograms represent averages ± SEM. * P < 0.05 for comparison with control-treated mice (Mann-Whitney U-test). CFA = complete 
Freund's adjuvant.Available online http://arthritis-research.com/content/11/4/R122
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bers of immature and mature neutrophils were observed in the
spleen of anti-IL-17-treated as compared with control-treated
mice. Although to a lesser degree, a significant reduction in
the number of macrophages in the splenocyte population of
anti-IL-17-treated mice was also seen. Treatment with anti-IL-
17 antibodies did not significantly affect the number of lym-
phocytes in the splenocyte preparations.
Anti-IL-17 treatment in IFN-γR KO mice decreases the 
production of hemopoietic cytokines
The reduced expansion of the CD11b+ cell population follow-
ing treatment with anti-IL-17 antibodies might result from inhi-
bition of the production of hemopoietic cytokines. Therefore,
sera of anti-CD3-challenged IFN-γR KO mice treated with anti-
IL-17 or control antibodies were collected on day 21 and
tested for the presence of cytokines. Levels of GM-CSF, IL-6
and IL-12, known to stimulate hemopoiesis, were significantly
reduced in the sera of mice treated with anti-IL-17 antibodies
as compared with control-treated mice (Figure 4d), possibly
providing an explanation for the reduced expansion of
CD11b+ cells in the spleen of anti-IL-17-treated mice. Expres-
sion of IFN-γ, known to inhibit the CFA-induced expansion of
CD11b+ cells, was also found to be significantly reduced upon
treatment with anti-IL-17. However, as IFN-γR KO mice were
used, levels of IFN-γ have no effect in our model. With regard
to the expression of other cytokines, levels of the pro-inflam-
matory cytokine TNF-α were slightly reduced upon treatment
with anti-IL-17 antibodies (1133.3 ± 658.6 and 721.9 ±
Figure 4
Anti-IL-17 antibody treatment reduces the splenic CD11b+ cell expansion and the systemic production of myelopoietic cytokines Anti-IL-17 antibody treatment reduces the splenic CD11b+ cell expansion and the systemic production of myelopoietic cytokines. Interferon-γ recep-
tor knock-out (IFN-γR KO) mice were immunized and injected intraperitoneally with anti-IL-17 or control antibody once a week. (a to c) On day 21, 
spleens of individual mice were isolated and splenocytes were counted. (a) Bars represent the mean number of splenocytes ± standard error of the 
mean (SEM). (b) Splenocytes were characterized by flow cytometry and the percentage of CD11b+ cells, CD11b+Gr-1high cells, B220+ cells, CD4+ 
cells and CD8+ cells was analyzed. Bars represent the mean net numbers of three independent experiments, each consisting of three to four mice 
per group ± SEM. (c) The percentage of lymphocytes, (immature) neutrophils and macrophages was assessed on cytospin splenocyte preparations 
of six anti-IL-17- and six control-treated mice, and the net numbers were calculated. Bars represent net numbers ± SEM. (d) At day 21 post immuni-
zation, mice were challenged with 10 μg anti-CD3 antibody and serum levels of granulocyte macrophage colony-stimulating factor (GM-CSF), IL-6, 
IL-12 and IFN-γ were determined 1.5 hours later. Bars represent the mean of two independent experiments, each consisting of four to five mice per 
group ± SEM. * P < 0.05 and ** P < 0.005 for comparison with control-treated mice (Mann-Whitney U-test).Arthritis Research & Therapy    Vol 11 No 4    Kelchtermans et al.
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562.3 pg/ml for the control- and anti-IL-17-treated mice,
respectively), and expression of all other tested cytokines (IL-
2, IL-4, IL-5 and IL-10) were comparable in the sera of both
groups of mice (data not shown).
IL-17 induces the production of IL-6, RANKL and GCP-2 in 
mouse embryo fibroblasts, and this induction is potently 
inhibited by IFN-γ
In a next set of experiments, we verified whether the absence
of bone destruction and reduced influx of neutrophils in the
joints, as well as the reduced production of hematopoietic
cytokines such as IL-6 upon anti-IL-17-antibody treatment, is
indirectly due to the reduced inflammation seen in these mice
or may directly result from neutralization of IL-17. As to the inhi-
bition of bone destruction, we compared the osteoclastogenic
capacity of splenocyte populations of immunized anti-IL-17-
treated and control-treated mice. Thus, splenocytes from both
groups of mice were stimulated with macrophage colony-stim-
ulating factor (M-CSF) and RANKL for induction of osteoclas-
togenesis. We found similar numbers and activity of
osteoclasts in both groups of mice (data not shown), indicat-
ing that osteoclast precursors are present in both splenocyte
populations. Possibly, the migration of these osteoclast pre-
cursors to the joints or the production of osteoclast stimulating
factors such as RANKL in the joints is disturbed in anti-IL-17-
treated mice. As fibroblasts are an important source of
RANKL, IL-6 and the neutrophil-specific chemokine GCP-2
([28]and our unpublished results), and because of the limited
source of mouse synovial fibroblasts, we chose to use MEF for
in vitro stimulation. Cells were stimulated with IL-17 in the
absence or presence of TNF-α for 48 hours, and mRNA levels
were measured using quantitative PCR. In addition, we tested
the effect of IFN-γ on the induction of RANKL, IL-6 and GCP-
2. As shown in Figure 5a, IL-17 induced the expression of
GCP-2 mRNA in MEF. Moreover, a synergy between IL-17
and TNF-α in the induction of GCP-2 mRNA could be
observed. These findings were confirmed at the protein level,
using a GCP-2-specific ELISA (Figure 5b). IL-17 and TNF-α
were also found to synergistically induce the expression of IL-
6 mRNA (Figure 5c), IL-6 protein (Figure 5d) and RANKL
mRNA (Figure 5e). These data indicate that IL-17 is able to
induce the production of neutrophil-specific chemokines such
as GCP-2. Through induction of IL-6 and RANKL, IL-17 can
stimulate hemopoiesis and bone destruction. Importantly,
expression of GCP-2, IL-6 and RANKL was counteracted by
IFN-γ (Figures 5a to 5e). Thus, aside from inhibition of the pro-
duction of IL-17, IFN-γ can inhibit the effector function of IL-17.
To exclude that IFN-γ non-specifically inhibits cytokine produc-
tion, we also tested the effect of IFN-γ on the production of
keratinocyte-derived chemokine (KC), macrophage inflamma-
tory protein (MIP)-2, IP-10, Regulated upon Activation, Normal
T-cell Expressed, and Secreted (RANTES), monocyte chemo-
tactic protein (MCP)-1, interferon-inducible T cell alpha chem-
oattractant (ITAC), and monokine induced by gamma
interferon (MIG). IFN-γ was found to exhibit stimulatory effects
on the production of MIP-2, IP-10, RANTES, ITAC and MIG
induced by IL-17 and/or TNF-α (Figure 5f and data not
shown). No significant effect of IFN-γ was observed on the
production of M-CSF, KC and MCP-1 (Figure 5f and data not
shown).
Inhibition of the effector function of IL-17 by IFN-γ is 
STAT-1- but not IRF-1-dependent
STAT-1 is a major mediator of cell activation by IFN-γ [33].
However, IFN-γ also activates STAT-1-independent pathways,
and it has been proposed that these STAT-1-independent
pathways mediate suppressive activities of IFN-γ. To investi-
gate whether suppression of GCP-2, IL-6 and RANKL expres-
sion by IFN-γ was STAT-1-dependent, MEF from wild-type and
STAT-1-/- mice of the C57BL/6 strain were prepared. At the
same time, we investigated whether the inhibition by IFN-γ was
dependent on IRF-1, a transcription factor acting immediately
downstream of STAT-1, by preparing MEF from IRF-1-/-
C57BL/6 mice. In each of the MEF, IL-17 and TNF-α synergis-
tically induced the expression of GCP-2, RANKL and IL-6
mRNA (data not shown). To evaluate the importance of STAT-
1 and IRF-1 in the inhibitory action of IFN-γ, the percentage of
inhibition of the expression of GCP-2, RANKL and IL-6 mRNA
induced by synergistic action of IL-17 and TNF-α was calcu-
lated and compared. As shown in Figure 6a, the inhibition by
IFN-γ was significantly reduced in STAT-1-/-, but unaffected in
IRF-1-/- MEF, as compared with wild-type MEF. For the inhibi-
tion of the expression of GCP-2, these results were confirmed
at the protein level (Figure 6b). These data indicate that the
inhibition by IFN-γ is STAT-1-, but not IRF-1-dependent.
Discussion
IL-17 plays a key inflammatory role in the propagation of RA
and CIA [11,34,35]. IL-17 promotes inflammation through
enhancing the production of inflammatory cytokines, such as
IL-1β, TNF-α and RANKL, as well as neutrophil-specific chem-
okines such as MIP-2 and IL-8 [4,5,36]. Inhibition of the IFN-γ
signaling enhances development of pathogenic Th17 cells
that can exacerbate autoimmunity [3,9]. IFN-γR KO mice have
been found to experience an accelerated and more severe
form of CIA [30]. Events contributing to this protective effect
of IFN-γ in CIA are inhibition of the CFA-induced myelopoiesis
and osteoclastogenesis, inhibition of the production of GCP-
2 and thus neutrophil infiltration, and stimulation of Treg cell
activity [23,27,28,31]. Recently, IFN-γ was found to regulate
susceptibility to arthritis through suppression of IL-17 [15,37].
Although Th17 cells and IL-17 have been studied extensively
in previous years, much of their effector functions remain
unknown. To observe maximal effects of IL-17 neutralization in
CIA, we chose to start from IFN-γR KO mice for the induction
of CIA. A preventive treatment with the anti-IL-17 antibodies
(starting from the day of the immunization), almost completely
abrogated arthritis development in IFN-γR KO mice and inhib-
ited the influx of immunocompetent cells (predominantly neu-
trophils), hyperplasia of the synovial membrane and boneAvailable online http://arthritis-research.com/content/11/4/R122
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Figure 5
Synergy of IL-17 and TNF-α in the induction of GCP-2, RANKL and IL-6 and inhibition by IFN-γ Synergy of IL-17 and TNF-α in the induction of GCP-2, RANKL and IL-6 and inhibition by IFN-γ. (a to d) Mouse embryo fibroblasts (MEF) cells of 
interferon-γ ligand knock-out (IFN-γ ligand KO) BALB/c mice were grown to confluence and stimulated for 48 hours with IL-17 (20 ng/ml) and/or 
TNF-α (20 ng/ml), or were left untreated in the absence or presence of IFN-γ (100 units/ml). (a, c, e and f) cDNA samples were prepared and sub-
jected to quantitative PCR analysis. The relative quantity of granulocyte chemotactic protein-2 (GCP-2), receptor activator of nuclear factor-κB lig-
and (RANKL), IL-6, IP-10 and granulocyte macrophage colony-stimulating factor (GM-CSF) mRNA in each sample was normalized to the quantity of 
18S RNA. (b, f) GCP-2, interferon-gamma-induced protein (IP-10) and GM-CSF protein present in the supernatants of stimulated MEF was meas-
ured by ELISA. (d) IL-6 protein present in the supernatants was quantified by the Bioplex system. Results represent the mean of two cultures ± 
standard error of the mean. Results are representative for (a, b) four and (c to f) two independent experiments.Arthritis Research & Therapy    Vol 11 No 4    Kelchtermans et al.
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destruction. Lubberts and colleagues found that treatment
with anti-IL-17 antibody after the onset of CIA significantly
reduces the severity of CIA in wild-type mice [12]. In line with
our results, lower numbers of multinucleated cells were
present in the joints of the anti-IL-17-treated mice as com-
pared with control mice.
IL-17 is known to be a potent stimulator of osteoclastogenesis
through induction of RANKL [10,38]. Nonetheless, if spleno-
cytes from immunized anti-IL-17-treated and control mice
were stimulated ex vivo with RANKL and M-CSF for induction
of osteoclastogenesis, in the absence or presence of exoge-
nously added neutralizing anti-IL-17 antibody, no differences
could be observed in the numbers or activity of osteoclasts
(data not shown). More recently, however, Sato and col-
leagues have demonstrated that IL-17 has no effect on osteo-
clastogenesis in the RANKL-M-CSF system, but promotes
osteoclast differentiation in the co-culture system through the
induction of RANKL on osteoblastic cells [39].
Joint inflammation in CIA is assumed to depend in part on col-
lagen-specific humoral and cellular immune reactivity. Treat-
ment with anti-IL-17 antibody resulted in reduced, although
not significantly, titers of total anti-CII IgG antibodies. No dif-
ferences in anti-CII IgG1 and IgG2b could be detected, but
significantly lower levels of anti-CII IgG2a in sera of anti-IL-17-
treated IFN-γR KO mice were established. As IgG2a and IgG1
kinetics indirectly reflect Th1/Th2 responses, these data are
suggestive for a lower Th1 response after treatment with anti-
IL-17 antibodies. IL-17 was previously shown to be important
in the induction of autoreactive humoral immune responses
because a deficiency in this cytokine is associated with a
decline in the autoantibody response in CIA and experimental
autoimmune encephalomyelitis [13,40]. Recently, IL-17 was
found to drive autoimmune responses by promoting the forma-
tion of spontaneous germinal centers [41]. With regard to the
cellular immune responses, we found significantly impaired
DTH to CII in IFN-γR KO mice treated with anti-IL-17 antibody.
In IL-17 KO mice, Nakae and colleagues have established sig-
nificantly reduced proliferative responses of lymph node cells
against CII in comparison with that of wild-type mice [13].
Taken together, these results demonstrate a crucial role for IL-
17 in the activation of CII-specific cellular responses.
As we reported earlier [31], the increased severity of CIA in
IFN-γR KO mice is associated with an increased CFA-induced
extramedullary expansion of immature CD11b+ macrophages
and neutrophils. In the present study we showed that anti-IL-
17 antibodies inhibit the expansion of this CD11b+ cell popu-
lation. Characterization of these CD11b+ splenocytes indi-
cated a significant reduction in the numbers of (immature)
neutrophils. The lower numbers of neutrophils present in the
spleen may provide an explanation for the reduced influx of
neutrophils in the joints of the anti-IL-17-treated mice. IL-17
has been found to act as a stimulatory hematopoietic cytokine
by expanding myeloid progenitors and initiating proliferation of
mature neutrophils [42]. It has been described to induce the
secretion of hematopoietic cytokines such as IL-6 and G-CSF
in fibroblasts, through which these stimulated fibroblasts can
sustain the proliferation of hematopoietic progenitors and their
Figure 6
Inhibition of effector functions of IL-17 by IFN-γ is STAT-1-dependent Inhibition of effector functions of IL-17 by IFN-γ is STAT-1-dependent. Mouse embryo fibroblasts (MEF) of wild-type, signal transducer and activator 
of transcription (STAT)-1-/- and interferon regulatory factor (IRF)-1-/- C57BL/6 mice were grown to confluence and stimulated for 48 hours with IL-17 
(20 ng/ml) and TNF-α (20 ng/ml), or were left untreated in the absence or presence of IFN-γ (100 units/ml). (a) cDNA samples were prepared and 
subjected to quantitative PCR analysis. The relative quantity of granulocyte chemotactic protein-2 (GCP-2), receptor activator of nuclear factor-κB 
ligand (RANKL) and IL-6 mRNA in each sample was normalized to the quantity of 18S RNA. (b) GCP-2 protein present in the supernatants of stim-
ulated MEF was measured by ELISA.(a, b) All cultures were performed in duplicate/triplicate in two independent experiments and the percentage of 
inhibition was calculated as 100 × (expression in condition without IFN-γ – expression in condition with IFNγ)/expression in condition without IFN-γ). 
Results represent the mean of five cultures ± standard error of the mean. * P < 0.05 for comparison with corresponding wild-type and, except for IL-
6, IRF-1-/- condition and ** P < 0.05 for comparison with corresponding wild-type and STAT-1-/- condition.Available online http://arthritis-research.com/content/11/4/R122
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preferential maturation into neutrophils [5]. In the same line, IL-
17R KO mice have impaired hemopoietic recovery following
gamma irradiation; hemopoietic precursors are reduced by
50% and neutrophils by 43% [43]. In the present study, the
reduced granulopoiesis observed in anti-IL-17-treated mice
probably resulted from reduced production of GM-CSF, IL-6
and IL-12. Treatment with neutralizing anti-IL-17 antibodies
after the onset of arthritis has also been demonstrated to result
in significantly reduced systemic IL-6 levels in wild-type mice
[12]. Along the same line, stimulation of various cell types with
IL-17 has been found to induce production of pro-inflamma-
tory mediators such as IL-6 and GM-CSF [4,44,45].
In a previous set of experiments we tested whether the
observed reduced influx of neutrophils in the joints, bone
destruction and hematopoiesis directly result from neutraliza-
tion of IL-17, or were a reflexion of the reduced inflammation
present in the anti-IL-17-treated mice. In mice, IL-8, the proto-
type of human CXC chemokines that mainly affect neutrophil
migration, has not been described, but the only neutrophil-
attracting chemokine recognizing CXCR1 and 2 is GCP-2,
generally considered as the functional equivalent of IL-8 in
humans [46,47]. We found that IL-17 and TNF-α synergisti-
cally induce the production of GCP-2, RANKL, IL-6 and GM-
CSF in MEF, thereby providing an explanation for the observed
phenomena upon neutralization of IL-17. The induction of IL-6
and RANKL by IL-17 has been described [4,48,49]. In addi-
tion, studies have already linked IL-17 to induction of neu-
trophil-specific chemokines such as IL-8 and MIP-2 and the
consequent effects on neutrophil recruitment [5,6,49]. More
recently, IL-17 was shown to promote the selective expression
of ELR+ CXC chemokines in RA synoviocytes, especially in the
presence of TNF-α, highlighting its role in neutrophil recruit-
ment into the joint [49]. Furthermore, IL-17 induces the pro-
duction of GCP-2 in a preosteoblast cell line and normal
mesenchymal cells [50,51]. Shen and colleagues have shown
that the CXC family chemokines, including KC, MIP-2 and
GCP-2, were dramatically induced by IL-17 and/or TNF-α
[48]. Recently, IL-17 was found to enhance cartilage destruc-
tion by increasing the production of KC and MIP-2, and
thereby the influx of Fcγ R-bearing neutrophils [52]. Impor-
tantly, we established an inhibition of this production of GCP-
2, RANKL and IL-6 upon addition of IFN-γ. Levels of other
tested cytokines induced by TNF-α/IL-17 were upregulated or
not affected by IFN-γ, indicating that inhibition was specific.
Although IFN-γ has been described to regulate neutrophil
influx through inhibition of the IL-1β-, TNF-α-driven or myco-
bacteria-driven production of IL-8 and/or GCP-2
[28,51,53,54], its effect on IL-17-induced gene expression
was so far not investigated. Using STAT-1-/- and IRF-1-/- MEF,
we found that the observed inhibition by IFN-γ is IRF-1-inde-
pendent, but STAT-1-dependent. Taken together, aside from
the well-known inhibition of the development of Th17 cells by
IFN-γ, we demonstrate that IFN-γ profoundly inhibits the effec-
tor function of IL-17 in a STAT-1-dependent way.
As levels of IL-17 were found to be significantly lower in wild-
type mice as compared with IFN-γR KO mice and because
IFN-γ profoundly inhibits the effector function of IL-17, we
expected the protective effect of anti-IL-17 in wild-type mice to
be less pronounced. However, a preventive anti-IL-17 anti-
body treatment significantly inhibited the clinical and histolog-
ical symptoms of arthritis in wild-type mice (with a total of 16
mice in each group, an incidence was reached of 54% and
13% respectively in control-treated and anti-IL-17-treated
wild-type mice). In an attempt to unravel the mechanism of pro-
tection, we analysed the effect of anti-IL-17 treatment on dif-
ferent effector targets. Whereas the CII cellular autoimmune
response (i.e. DTH) was found to be reduced by half upon
treatment with anti-IL-17 antibody, the production of anti-CII
autoantibodies and the splenic expansion of CD11b+ cells
were not affected (data not shown). Thus, although anti-IL-17
antibody is effective in reducing the clinical symptoms of arthri-
tis in both IFN-γR KO and wild-type mice, the mechanism of
endogenous IL-17 in the pathogenesis of CIA appears to be
somewhat different between the two groups of mice.
It is generally accepted that different pathways, such as
humoral and cellular immune responses, myelopoiesis and
osteoclastogenesis are all required to develop CIA. Depend-
ing on the presence or absence of IFN-γ, IL-17 mediated sev-
eral of these processes and it can be speculated that blocking
just one of these pathways, for example DTH, may be sufficient
to prevent symptoms of arthritis. Alternatively, there may exist
a profound effector mechanism of IL-17 in both IFN-γR KO and
wild-type mice that has not been investigated in our study and
still needs to be discovered.
Conclusions
In conclusion, our experiments underscore that IL-17 mediates
its pro-inflammatory role in CIA in IFN-γR KO mice mainly
through stimulatory effects on granulopoiesis, neutrophil infil-
tration and bone destruction. Importantly, our data reveal also
an additional mechanism through which IFN-γ can attenuate
some autoimmune diseases and autoimmune arthritis in partic-
ular. Apart from the inhibition of the production of IL-17, IFN-γ
also abrogates some of the effector functions of IL-17. Thus,
through its inhibition of the IL-17-induced production of IL-6,
GCP-2 and RANKL, IFN-γ can profoundly limit granulopoiesis,
mobilisation of neutrophils, and bone destruction, which are all
important in joint inflammation.
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